HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Trims US Retail Profile While Exiting Contract Manufacturing

This article was originally published in The Tan Sheet

Executive Summary

The Vitamin World deal jettisons one of NBTY's slower-performing businesses after the firm previously began exiting the low-margin contract manufacturing sector. The acquisition by a Centre Lane Partners unit is the second private equity move in the supplement space in two weeks.

You may also be interested in...



Carlyle Trims Nature's Bounty Assets: Private Equity Rolls In Supplement Space

Carlyle's $2.2bn sale of Nature's Bounty's Holland & Barrett business to a Russian investment fund is the latest sign of the private equity sector's continuing interest in the health and wellness space.

GNC 'Broken Business' Repair: Single-Tier Pricing, Free Loyalty Program

Interim CEO Robert Moran says "we found … a badly broken business in need of change" since he took the helm in July. The broken parts include a loyalty program not driving sales; inconsistent and confusing pricing; and point-of-sale checkout failures.

Swanson Health Sale Could Lead Private Equity Spike In Supplement Space

Swander Pace Capital's Swanson Health deal announced Jan. 25 is the firm's second in two months in the supplement industry after acquiring Captek Softgel in December. OTC drug and supplement firms in 2016 could be among the consumer product spaces targeted in likely higher private equity investing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel